scholarly article | Q13442814 |
P356 | DOI | 10.1038/NCPENDMET0532 |
P698 | PubMed publication ID | 17519916 |
P50 | author | Steven I. Sherman | Q43011758 |
P2860 | cites work | Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 |
A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later | Q40411768 | ||
Surrogate end points in clinical trials: are we being misled? | Q41117631 | ||
Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients | Q79319487 | ||
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer | Q82293286 | ||
P433 | issue | 7 | |
P921 | main subject | thyroglobulin | Q20817224 |
P304 | page(s) | 510-511 | |
P577 | publication date | 2007-05-22 | |
P1433 | published in | Nature Clinical Practice Endocrinology and Metabolism | Q15750240 |
P1476 | title | Can serum thyroglobulin levels predict patient outcome after treatment of differentiated thyroid carcinoma? | |
P478 | volume | 3 |
Search more.